Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Na ïve Type 2 Diabetes Mellitus Patients
CONCLUSION: Initial triple combination therapy with metformin, sitagliptin, and empagliflozin led to achievement of the glycemic target goal, which was maintained for 24 months without severe hypoglycemia but with improved metabolic function and albuminuria. This combination therapy may be a good strategy for drug-naïve patients with type 2 diabetes mellitus.PMID:38273791 | DOI:10.4093/dmj.2023.0128
Source: Diabetes and Metabolism Journal - Category: Endocrinology Authors: Young-Hwan Park Minji Sohn So Yeon Lee Soo Lim Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Fatty Liver Disease (FLD) | Fortamet | Insulin | Janumet | Januvia | Jardiance | Liver | Metformin | Sodium | Urology & Nephrology